- Home
- BWIN vs PTGX Comparison
BWIN vs PTGX Comparison
Compare BWIN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- PTGX
- Stock Information
- Founded
- BWIN 2011
- PTGX 2006
- Country
- BWIN United States
- PTGX United States
- Employees
- BWIN N/A
- PTGX N/A
- Industry
- BWIN Specialty Insurers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- PTGX Health Care
- Exchange
- BWIN Nasdaq
- PTGX Nasdaq
- Market Cap
- BWIN 2.9B
- PTGX 3.3B
- IPO Year
- BWIN 2019
- PTGX 2016
- Fundamental
- Price
- BWIN $40.64
- PTGX $55.15
- Analyst Decision
- BWIN Buy
- PTGX Strong Buy
- Analyst Count
- BWIN 7
- PTGX 9
- Target Price
- BWIN $44.67
- PTGX $67.11
- AVG Volume (30 Days)
- BWIN 594.7K
- PTGX 790.5K
- Earning Date
- BWIN 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- BWIN N/A
- PTGX N/A
- EPS Growth
- BWIN N/A
- PTGX N/A
- EPS
- BWIN N/A
- PTGX 0.86
- Revenue
- BWIN $1,422,075,000.00
- PTGX $207,801,000.00
- Revenue This Year
- BWIN $12.74
- PTGX N/A
- Revenue Next Year
- BWIN $14.05
- PTGX $53.09
- P/E Ratio
- BWIN N/A
- PTGX $63.95
- Revenue Growth
- BWIN 12.11
- PTGX N/A
- 52 Week Low
- BWIN $34.22
- PTGX $32.50
- 52 Week High
- BWIN $55.82
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- BWIN 48.77
- PTGX 56.72
- Support Level
- BWIN $40.15
- PTGX $51.55
- Resistance Level
- BWIN $41.60
- PTGX $57.73
- Average True Range (ATR)
- BWIN 1.37
- PTGX 1.74
- MACD
- BWIN -0.15
- PTGX -0.07
- Stochastic Oscillator
- BWIN 31.82
- PTGX 69.13
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.